ATLAS fair value
₩6,844
Close to fair value · 3% premium
CHA Biotech stock price today, ATLAS forecast and fair value
Healthcare · Biotechnology · KOSDAQ · South Korea
Prices as of Oct 27, 2026 · KRW
₩6,844
Close to fair value · 3% premium
49%
that it ends higher than today in 21 sessions
ATLAS's own quantitative analysis, all in one place.
Plans from €3.99 a month.
ATLAS estimates CHA Biotech's fair value at about ₩6,844 per share (reasonable range: ₩2,484 to ₩18,670). At ₩7,030, the stock trades within 8% of that figure: close to fair value.
It is calculated with valuation multiples of comparable companies. Confidence in the estimate is low. It is an estimate, not a promise: if the company's results change, so does its fair value.
ATLAS's model gives CHA Biotech a 49% chance of finishing higher a month from now (21 trading sessions) than today: close to a coin flip.
In half of the simulated outcomes the price ends between ₩6,439 and ₩7,613; in 9 out of 10, between ₩5,551 and ₩8,832. Estimated annual volatility is 48%.
These are two different questions: fair value looks at the business (what it is worth given what it earns) and the odds look at the price over the next month. CHA Biotech sits close to fair value and its odds of rising over a month are close to a coin flip. An expensive stock can keep climbing and a cheap one can keep falling, which is why ATLAS shows the two readings separately.
Over the last 52 weeks 085660.KQ has traded between ₩7,000 and ₩23,950. Today it is 70.7% below that high and 0% above its low.
On the business: net margin is 1.1%; it trades at 49.3 times earnings.
Its beta is 0.57: it tends to move less than the market.
Chabiotech Co.,Ltd., a bio company, develops cell and gene therapy related to stem and immune cells in South Korea and internationally.
Want to see everything about CHA Biotech?
Get started →Plans from €3.99 a month.
Other companies in the same line of business:
About ₩6,844 per share according to ATLAS (reasonable range: ₩2,484 to ₩18,670). With the stock at ₩7,030, it is close to that value.
49%: close to a coin flip. In half of the simulated outcomes, 085660.KQ ends the month between ₩6,439 and ₩7,613.
CHA Biotech's market capitalization is ₩673B. Its price-to-earnings (P/E) ratio is 49.3: you pay ₩49.3 for each ₩1.00 of yearly earnings.
ATLAS estimates annual volatility at 48%. In a typical month, half of the outcomes end between ₩6,439 and ₩7,613.
Not investment advice. ATLAS estimates are produced by statistical models from public data; they can be wrong and past performance does not predict future results. Consider your own situation before investing. Disclaimer
ATLAS Signals
The week in the market, three stocks on ATLAS’s radar and what comes next. Get it every Monday.
By subscribing you agree to receive ATLAS Signals by email every Monday. You can unsubscribe with one click at any time. Privacy